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ABSTRACT
Intraneural accumulation of misfolded proteins is a common feature of several neurodegenerative pathologies including
Alzheimer’s and Parkinson’s diseases, and Familial Encephalopathy with Neuroserpin Inclusion Bodies (FENIB). FENIB is
a rare disease due to a point mutation in neuroserpin which accelerates protein aggregation in the endoplasmic reticulum
(ER). Here we show that cholesterol depletion induced either by prolonged exposure to statins or by inhibiting the sterol
regulatory binding-element protein (SREBP) pathway also enhances aggregation of neuroserpin proteins. These findings can
be explained considering a computational model of protein aggregation under non-equilibrium conditions, where a decrease
in the rate of protein clearance improves aggregation. Decreasing cholesterol in cell membranes affects their biophysical
properties, including their ability to form the vesicles needed for protein clearance, as we illustrate by a simple mathematical
model. Taken together, these results suggest that cholesterol reduction induces neuroserpin aggregation, even in absence of
specific neuroserpin mutations. The new mechanism we uncover could be relevant also for other neurodegenerative diseases
associated with protein aggregation.
Introduction
Conformational diseases, such as Alzheimer’s and Parkinson’s diseases, spongiform encephalopathies and serpinopathies,
are an increasingly common class of neurological disorders characterized by the aggregation of aberrant conformations of
proteins. Familial Encephalopathy with Neuroserpin Inclusion Bodies (FENIB)1, 2 is an autosomal dominant inclusion body
dementia characterized by protein aggregation within the endoplasmic reticulum (ER) .1, 2 FENIB is associated with mutations
in neuroserpin,3 a protein belonging to the superfamily of serpins that plays an important role in brain development, neuronal
survival, and synaptic plasticity .4 Indeed, mutants of neuroserpin in FENIB patients show accelerated rates of polymerization
compared with wild type proteins, both at the protein level in vitro 5, 6 and in cell models .1, 2 Moreover, neuroserpin is the
most important inhibitor of the tissue plasminogen activator (tPA) in the brain which is known to be increased in Alzheimer’s
disease.7–9
Lipid metabolism has been shown to play a role in FENIB, but also in other neurodegenerative diseases, from Alzheimer’s
to Parkinson’s disease .10–13 In FENIB the inhibition of hydroxymethyl glutaryl-CoA reductase (HMGCR) has a critical role in
the clearance of mutant neuroserpin from the ER .13 Numerous studies have also reported that the modification of cholesterol
content can affect amyloid precursor protein (APP) processing, which is needed for neuronal activity .11 In this connection,
it has been shown that the E693D (Osaka) mutation in APP promotes intracellular accumulation of Amyloidβ (Aβ ), thus
disturbing amyloid-mediated cholesterol efflux from the cell.14 Cholesterol has also been shown to influence APP processing
and Aβ generation by modulating Aβ - and Amyloid-γ-secretase activities .15–18 In turn, APP cleavage products regulate
cholesterol homeostasis .19
In a recent paper, our group has shown by 3D numerical simulations and mean-field calculations that protein aggregation
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undergoes a non-equilibrium phase-transition controlled by the rates of protein synthesis and degradation, suggesting a crucial
role of intracellular trafficking, particularly from the ER .20 According to this study, a decrease in the rate of protein clearance
from the ER can lead to rapid and irreversible protein aggregation in the ER itself,20 leading to the onset of neurodegenerative
diseases.
Cholesterol plays a crucial role in regulating the properties of phospholipid membranes, affecting their fluidity and
rigidity,21–23 the function and dynamics of membrane proteins,24, 25 and thus vesicular trafficking within the cell.26–28 Hence,
by regulating the biosynthesis of cholesterol it is possible to affect the form and function of all the membranes within the cell,
including the ER. In particular, experiments show that lowering the level of cholesterol delays ER-to-Golgi transport.28, 29
Cholesterol homeostasis is controlled by a family of transcription factors, known as sterol regulatory element binding
proteins (SREBPs) .30 In cells with sufficient cholesterol supply, SREBPs are transmembrane proteins retained in the ER,
associated with SREBP-cleavage-activating protein (SCAP), a cholesterol sensor .31 Upon cellular cholesterol depletion,
SREBP leaves the ER to reach the Golgi, where cleavage by site-1 protease (S1P) releases the amino-terminal half of SREBP,
which can be further cleaved within its membrane-spanning helix by site-2 metalloproteinase (S2P) .32 The mature processed
form of SREBP is released in the cytosol and can translocate into the nucleus where it modulates the expression of several
genes controlling cholesterol and fatty acid homeostasis ,33 including HMGCR, HMG-CoA synthase (HMGCS), low density
lipoprotein receptor (LDLR) and SREBP1/2 itself. SREBP1 activates fatty acid synthesis and SREBP2 cholesterol synthesis
and uptake .34
In this paper, we combine experiments and computational analysis to show that lowering the level of cholesterol either by
using statins or by inhibiting SREBP1 and SREBP2 pathways with the small molecule betulin has a significant impact on the
aggregation of non-mutated neuroserpin within the cell. Statins are competitive inhibitors of HMGCR, a rate limiting enzyme
for cholesterol levels. They are widely used as plasma cholesterol lowering drugs in dyslipidemic patients. In spite of the clear
effect of statins in lowering morbidity and mortality, in particular in cardiovascular events, many recent studies suggest that
prolonged use of statins in Alzheimer’s disease patients leads to mixed outcomes and could contribute to statin-adverse effects
.35–39 Whereas current guidelines encourage an aggressive use of statins to achieve long-term cholesterol lowering in order to
decrease cardiovascular events, the resulting effect on cell membranes is unknown. Here, we focus our experimental analysis
on non-mutated (wild type) neuroserpin and directly observe a dramatic increase in aggregates when cells are chonically
exposed to statins. To confirm the direct involvement in aggregation of lower cholesterol levels, we use betulin, a pentacyclic
triterpene commonly isolated from the birch bark, that specifically inhibits the maturation of SREBPs by enhancing interaction
between SCAP and INSIG thus promoting SREBPs retention in the ER.40 Also in this case, we observe lower cholesterol
and more neuroserpin aggregation. Our findings are consistent with a cholesterol induced decrease in the protein clearance
rate, leading to faster aggregation in our model.20 To elucidate the biophysical mechanism underlying this observation, we
study a mathematical model of coated vesicle release from lipid membranes, illustrating the crucial role of cholesterol for
vesicle formation and therefore the impact of its unbalance on intracellular trafficking. Taken together, our results suggest that
long-term treatment with statins may affect intracellular trafficking in a way to enhance protein aggregation.
Results
Prolonged treatment with statins enhances neuroserpin aggregation in HeLa cells
Simvastatin (SIM), pravastatin (PRA) and rosuvastatin are all known to be inhibitors of cholesterol synthesis by acting on
HMGCR. PRA is, however, reported to be less effective both in patients and in vitro due to its hydrophylicity .41 We test
the effect of long-term (i.e. up to 8 days) treatment with statins (5µM SIM or 10µM PRA or 0.1µM rosuvastatin or 1µM
rosuvastatin) on the capability of neuroserpin to aggregate in HeLa cells. Fig. 1a shows that, in native gel, the treatment with
SIM is able to induce multiple bands of neuroserpin, suggesting the presence of aggregates. We obtain similar results for
the more powerful drug rosuvastatin, as reported in Fig. 1b .42 In contrast, the exposure to PRA does not affect neuroserpin
aggregation, as shown in Fig. 1a. To directly confirm the presence of neuroserpin aggregates after prolonged treatment with
statins, we use the Duolink in Situ staining. Using this technique allows the detection of a fluorescent spot if at least two
monomers of neuroserpin protein are in close proximity, such as when they form a dimer. We mix (1:1) HeLa with HeLa-GFP
cells to confirm that possible aggregation is independent from the specific cell line used. Moreover, in HeLa—GFP cells the
cytoplasm is green. We then treat the cells with statins for up to 8 days. Long-time treatment (8 days) with 5µM SIM or 0.1µM
rosuvastatin induces neuroserpin aggregation while shorter incubation times with 5µM SIM or 8 days of treatment with 10µM
PRA do not induce any effect, as shown in Fig. 2. Moreover, 8 days of treatment with 0.1µM rosuvastatin gives a stronger
effect with respect to 5µM SIM Fig. 2 and Fig. 3.
Effect of the treatment with SIM, rosuvastatin or PRA on cholesterol and HMGCR levels in HeLa cells
Filipin is commonly used to detect cholesterol, but it is not very stable, rapidly photobleaches and results in acute toxicity
for living cells.43 To avoid these problems, we use a fluorescently labeled theonellamide (TNM-AMCA). TNM-AMCA was
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originally isolated from a marine sponge, and has been reported to bind in a specific manner to the 3β -hydroxyl group of
cholesterol without acute toxicity .44–46 5µM SIM, 0.1µM rosuvastatin or 20µM betulin affect the level of cholesterol after 8
days of treatment (Fig. 4 and Fig. 3), while PRA is less effective and does not change significantly the level of cholesterol41
(Fig. 4). Finally we investigate by western blot whether the treatment with statins affects the expression level of the key enzyme
of cholesterol synthesis, HMGCR. As shown in Fig. 1c, no significant changes in the level of expression of this enzyme occurs
after long-time treatment either with SIM or PRA.
Effect of the treatment with SIM, rosuvastatin or PRA on the level of expression of SREBP1 and SREBP2
SREBPs are transmembrane proteins expressed at the level of ER, associated with SCAP which is a cholesterol sensor .31
Intracellular trafficking of SREBPs is sensitive to cholesterol depletion: when the level of cholesterol is reduced, SREBP
leaves the ER to reach the Golgi where it is cleaved. Then, the mature processed form of SREBP is released in the cytosol
and translocates into the nucleus where it modulates the expression of several genes controlling cholesterol and fatty acid
homeostasis33 and SREBP1/2 itself. Furthermore, it is known that SREBP1 regulates fatty acid synthesis and SREBP2
cholesterol synthesis and uptake .34 We thus investigate by immunofluorescence the effect of statins on the level of expression
of SREBP1 and SREBP2. Fig. 5 shows that SREBP1 is not affected by the either SIM or PRA treatments and SREBP2
increases significantly after 8 days of treatment with SIM. Rosuvastatin, in contrast, affects mainly SREBP1 (Fig. 6a).
Effect of the treatment with betulin on the level of expression of cholesterol, neuroserpin aggregation,
SREBP1 and SREBP2
An alternative route to interfere with the cholesterol level and study its effect on neuroserpin aggregation is to inhibit SREBPs
activity using betulin, a small molecule that is known to inhibit the maturation of SREBP by inducing interaction of SCAP and
Insig.40, 47 Betulin induces a decrease of cholesterol after 8 days of treatment (Fig. 3)40 and an accumulation of the precursor of
SREBPs (pre-SREBP), in agreement with Ref.4849 (Fig. 6b). Under these conditions, we show that the treatment for 8 days
with 20µM betulin induces neuroserpin aggregation (Fig. 1 and Fig. 3a).
Computational simulations reveal aggregation induced by the impairment of intracellular trafficking
In a previous paper our group developed a model three dimensional to explain the critical role for protein aggregation of
the non-equilibrium conditions in the ER.20 Here we implement the model in order to understand how the impairment of
intracellular trafficking might induce protein aggregation. The model performs coarse—grained simulations of diffusing
monomers and polymers in a closed system, representing the ER, under a constant rate of protein production kin. Proteins
exit the ER with a rate kout when they are close to the boundaries simulating vesicular trafficking. Hence, the parameter kout
encapsulates the efficiency of intracellular trafficking which can be affected by the level of cholesterol in the cell. Fig. 7a
shows that reducing kout, which should simulate an impairment in the intracellular trafficking leads to an increase in protein
aggregation, thus recapitulating in silico the experimental observations.
Mathematical model illustrates mechanical regulation of vesicle formation
The mechanism by which the level of cholesterol determines the value of kout is related to its role in affecting the biophysical
properties of membranes21–25 and thus their ability to form the vesicles needed for intracellular trafficking.26–28 Vesicle
formation in the ER is assisted by the Coat protein complex II (COPII) that is recruited on the surface of the ER membrane.50
The COPII complex self-assembles into a cage structure that encapsulate the lipid membrane forming a vesicle.51 The success
of the process crucially depends on the binding strength of the COPII to the membrane and on its bending stiffness, as we can
illustrate by a simple mathematical model. We considers an elastic membrane coupled to a curvature induced coat, representing
the action of a COPII cage in the ER. The model, described in details in the methods section includes two key dimensionless
parameters: i) the ratio between the bending stiffness of the membrane Km and the one of the coating scaffold Ks, and ii) the
ratio between the scaffold bending energy and its interaction energy with the membrane εLJ . Simulations show that vesicle can
only form is Km/Ks is small and εLJ/Ks is sufficiently large. For larger values of Km/Ks, the coating scaffold is not able to bend
the membrane into a vesicle while if εLJ/Ks is small the coat detaches from the membrane. This behaviour is summarized in the
phase diagram reported in Fig. 7b. A reduction in the level of cholesterol in the ER membrane affects both Km21–23 and εLJ ,29
thus displacing the system in different regions of the phase diagram. In particular, experiments show that cholesterol depletion
leads to a reduced recruitment of the Sec23p component of the COPII complex on the ER membrane, delaying ER-to-Golgi
transport.29
Discussion
Long-term lowering serum low density lipoprotein cholesterol with statin drugs is used extensively and has proven very effective
to reduce the incidence of cardiovascular events. De-novo cholesterol which is the target of statin therapy is found in all
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membranes and lipid based bodies, contributing to vesicle formation and migration, as well as other membrane functions .52
We can therefore expect that regulating the biosynthesis of cholesterol could change the form and function of every membrane
within the cell. For this reason, statin therapies could also cause potential harm.53 The role of ER in the aggregation of misfolded
proteins, such as neuroserpin, and therefore as a crucial determinant of cellular toxicity, is important in many neurodegenerative
diseases. Our group recently demonstrated the presence of a phase transition towards rapid protein aggregation due to a
breakdown of homeostasis in intracellular organelles, such as the ER, controlled by the rates of protein synthesis and clearance,
kin and kout, respectively .20 The open question stated in the conclusions of our earlier paper was related to the identification of
possible biological processes and factors that would tune these key parameters into an aggregation-prone pathological phase .20
In the present paper, we combine experiments and computational models to investigate this critical issue.
We focus our attention on cholesterol depletion by statins as a potential inhibitor protein clearance from the ER. We
investigate three different statins in a chonic treatement (8 days): SIM, rosuvastatin and PRA. Rosuvastatin has been shown to
be more effective than SIM ,42 while PRA is less effective when compared with SIM.41 Here we show indeed that long-term
treatment with SIM or rosuvastatin decreases the level of cholesterol, increases the level of expression of SREBP, compensating
for cholesterol depletion, and finally enhances neuroserpin aggregation even in the absence of specific mutations. In contrast,
PRA is less effective than the others two statins and therefore does not affect neither the level of cholesterol nor neuroserpin
aggregation .41
To ensure that the aggregation we observe for neuroserpin is really due to the lowering of cholesterol in the cell rather to a
direct interaction between statins and neuroserpin, we interfere with the cholesterol level indirectly by targeting SREBP through
betulin, whose action ultimately leads to cholesterol depletion.40 We found that betulin decreases the level of cholesterol
and accumulates pre-SREBPs.40, 48, 49 Also in this case, we find an enhancement of neuroserpin aggregation after long term
treatment (8 days).
It is well known that N-glycosylation plays determinant roles in protein folding and trafficking, and N-glycosylated proteins
are especially important in regulating extracellular activities. Recent papers show that aberrant N-glycosilation happens
frequently in relation to human diseases, including Alzheimer’s54 and FENIB, as pointed out in a recent paper.55 Furthermore,
a systematic and quantitative analysis of surface proteins was carried out in HepG2 liver cells treated with statin showing that
many glycosilation sites are downregulated compared to untreated cells .56 On the other hand, statins inhibit the pathway of
dilichol, which plays a critical role in protein N-glycosilation and acts as a membrane anchor for the formation of a precursor
oligosaccharide .57 Therefore, the long-treatment with statins could lead to important impairment of intracellular trafficking,
effectively decreasing the clearance rate kout .20 This is shown directly by numerical simulations of a protein aggregation model
where reducing kout leads to faster aggregation.
The role of cholesterol on the biophysical properties of lipid membranes has been the subject of extensive experimental
investigation. It is known that the level of cholesterol affects the membrane bending stiffness Km21–23 the dynamics of membrane
proteins24, 25 and has thus an effect on vesicle formation and trafficking.26–28 In particular, experiments show that the attachment
of coating proteins, such as COPII, to membranes is dependendent on cholesterol.29 Here, we develop simple mathematical
model that can incorporate into a single framework all this experimental observations and help predict the effect of statins on the
intracellular trafficking. While the model is too simple to provide a quantitative explanation of vesicle formation in dependence
on the cholesterol level, the phase diagram illustrates the possibility that small changes of key membrane biophysical parameters
such as the bending stiffness or the binding affinity of coat proteins, all known to be affected by cholesterol, result in a net
impairment of vesicle formation.
Recent results in the literature show an increased level of neuroserpin in Alzheimer’s disease patients, the critical role of tPA
and the association between neuroserpin and Aβ plaques in Alzheimer’s brain tissues.58 Our paper shows that neurosperpin
aggregation can be modulated by environmental factors affecting intracellular trafficking, even in the absence of deleterious
mutations that are known to induce aggregation.1, 2, 5, 6 The aggregation mechanism we propose is fairly general, depending
only on the modification of kinetic rates for protein clearance and it could therefore be relevant also for other neurodenerative
pathologies. For instance, it would be extremely interesting to clarify the possible role of statins in Aβ aggregation and more
generally on the development of Alzheimer’s disease.
Methods
Cell lines and treatments
Human Hela cells (ATCC-CRL-2) or HeLa-GFP cells (AKR-213 Cell Biolabs Inc.) were cultured in 80%DMEM, 10% FBS
with the addition of 1% antibiotics and 1% L-glutamine at 37◦C / 5% CO2. SIM (S-6196, Sigma) needs to be activated by
opening of the lactone ring before use in cell culture. We used the protocol described by .59 Briefly, 40mg/ml of SIM were
dissolved in 100% ethanol with subsequent addition of 0.1N NaOH .59 The solution was heated at 50◦C for 2h and then
neutralized with HCl to pH 7.2. The resulting solution was bought to a final volume (1ml) with distilled water and aliquots
were stored at -80◦C for no more then 3 months. Rosuvastatin (SML1264, Sigma) was dissolved in DMSO stock solution
4/16
(20mM) and stored in aliquots at -20◦C. Pravastatin (P4498 Sigma) was dissolved in distilled water and stored in aliquots at
-80◦C. Betulin (B9757, Sigma) was dissolved in 100% etanol (500µM) and stored in aliquots at -20◦C. The medium has been
replaced every 4 days with fresh medium containing statins or betulin or fresh medium for untreated cells.
Immunofluorescence
Subconfluent cells were fixed with 3.7% paraformaldeide, incubated with 0.1%Triton X-100 in PBS for 15min at room
temperature, then with 3%BSA in PBS for 30min at room temperature and finally with anti-SREBP-1 (1:100, ab28481
Abcam. 3.7% PFA fixed cells were incubated with 1% BSA/10% goat serum/0.3M glycine/0.1% tween in PBS for 1h at
room temperature and incubated with anti-rabbit (1:250, Alexa Fluor 488, ab 150077) for 1h at room temperature. 1µg/ml
Actinstain-555 phalloidin (Cytoskeleton Inc) is used to stain actin for 1h at room temperature. The nuclei were counterstained
with DAPI and the slides mounted with Pro-long anti fade reagent (Life technologies). The images were acquired with a Leica
TCS NT confocal microscope.
Duolink assay
Subconfluent cells were fixed with 4% paraformaldeide and incubated with 0.1%Triton X-100 in PBS for 15min at room
temperature, then with 5%BSA in PBS for 1h at room temperature and finally incubated with anti-neuroserpin (ab32901
AbCam) coniugated PLA probes (1:50) overnight at 4◦C. We detected neuroserpin aggregates with Duolink In Situ staining.
The Duolink In Situ staining are based on in situ PLA, which is a proximity ligation assay technology. A pair of oligonucleotide
labeled secondary antibodies (PLA probes) generates a signal only when the two PLA probes have bound in close proximity (at
a distance of less than 40nm), either to the same primary antibody or to two primary antibodies bound to the sample in close
proximity. The signal from each detected pair of PLA probes is visualized as an individual fluorescent spot. Duolink In Situ
Probemaker PLUS enables quick and convenient conjugation of the PLA PLUS oligonucleotide arm directly to the primary
antibody (DUO92009 and DUO92010 for PLUS and MINUS probe). The cross reacted proteins were detected according to
the manufacturer’s instruction (sigma.com/duolin, section 7.3 Detection protocol). The nuclei were mounted with Duolink
in situ mounting medium containing DAPI (DUO82040, Sigma). The images were acquired with a Leica TCS NT confocal
microscope. These PLA signals were quantified as described in the section spot detection.
Cholesterol staining
Cells were fixed with 4% paraformaldehyde (PFA) in PB 0.1M for 10 minutes at room temperature (RT). Then, they were
incubated with 50µg/ml Digitonin for 5 minutes and then for 1 hour with 4% Bovine Serum Albumin (BSA) in PBS. The
cells were then incubated with TNM-AMCA (1µM, gently gifted by Shinichi Nishimura and Minoru Yoshida, RIKEN Center
for Sustainable Resource Science, Saitama, Japan) for 1 hour. All the specimens were mounted with Fluoromount Aqueous
Mounting Medium without DAPI (Sigma-F4680) and the images were acquired with Leica SP2 laser scanning confocal
microscope.
Western Blot
Confluent cells were lysed by boiling in a modified Laemmli sample buffer (2% SDS, 20% glycerol, and 125 mM Tris-HCl,
pH6.8). The protein concentration was measured by BCA Protein Assay Kit (Thermo Scientific). Equal amount of proteins
were loaded on gel and separated by SDS-PAGE and transferred to a PVDF membrane (Whatman). After blocking, primary
and HRP-linked secondary antibodies, specific bindings were detected by chemiluminescence system (GE Healthcare). Goat
polyclonal antibody anti-neuroserpin (1:500, ab32901, AbCAM) or rabbit anti-HMGCR (1:1000, MAB5374, Millipore) or
anti-SREPB1 (1:500, ab28481, AbCam) or anti-SREBP2 (1:100, ab30682, AbCam) were used overnight at 4◦C. Mouse
anti-vinculin (1:10000, V9264, Sigma) or anti-al pha Tubulin antibody (1:5000, Sigma) for 1h at room temperature was
used as housekeeping. A secondary antibody anti goat-HRP (1:5000, ECL Blotting reagents (GE Healthcare RPN2109) /
SuperSignalTMWest Femto Maximum Sensitivity Substrate, Thermo scientific) was used for 1h at room temperature to detect
chemiluminiscence.
For non denaturating gels, cells were resuspended in 50mM Tris-HCl, pH7.4 containing 5mM EDTA, 1% Triton-X100 and
Protease inhibitors cocktail (1ml/100ml lysate, P8340, Sigma), passed for 4 times through an insulin syringe and maintained
in ice for 20min. After a brief centrifugation, the protein concentration was measured by BCA Protein Assay Kit (Thermo
Scientific). 100µg protein were loaded on 10% non denaturating gel, transferred on PVDF membrane as described above. The
PVDF membrane was reversible stained with Ponceau S solution (P7170, Sigma) to verify the correct loading of the samples.
Spot detection
Image analysis of Duolink In Situ staining was performed using the bioimage informatics platform Icy.60 To detect spots,
we first use the Thresholder plugin to eliminate the random noise in the images. We used the automated mode so that the
algorithm automatically calculates the optimal threshold value. We then applied the Spot Detector plugin61 that is based on an
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UnDecimated Wavelet Transform tool designed to detect spots. Then, we used the default values, enabling the scale=2 setup
with a threshold equal to 100 and a size filter to accept only spots with a size bigger than three pixels. We also extracted the
number of cell nuclei and compute the ratio between the number of spots and the number of cells.
Statistical Analysis
Statistical significance analysis is performed using the Kolmogorov-Smirnov test.
Polymer aggregation model
Simulations are performed using the protein aggregation model described in Ref.20 where individual protein molecules sit on a
three dimensional cubic lattice. Monomers diffuse with rate kD and attach to neighboring monomers or polymer endpoints with
rate kH. Polymers move collectively by reptation with a length-dependent rate kR/i2, where i is the number of monomers in the
polymer, and locally by end rotations, with rate kE and kink motions with rate kK. A polymer can attach to another polymer
with rate kH if their endpoints meet, and can fragment by breaking an internal bond with rate kf. Inspired by experimental
results on neuroserpin polymerization,62 we allow for polymerization after at least one of the monomers has been activated with
rate kA. Active monomers can also become latent with rate kL and after that they do not aggregate. We consider a system of
size (L×L×H) with L = 100L0 and H = 25L0, where L0 is the linear size of a monomer, with periodic boundary conditions
along x and y and closed boundary conditions along z. Monomers enter the system from both closed boundaries with rate
kin and monomers and polymers can exit from the same boundaries with rate kout/i3. Numerical simulations are performed
using Gillespie Montecarlo algorithm.63 We measure time in units of 1/kin and set kH = kE = kR = kK = kA = kin, kL = 0,
kD = 102kin, kf = 10−3kin and vary kout.
Vesicle formation model
We consider a simple model with three basic interaction energies: two bending energies related, respectively, to the elasticity of
the membrane and external cage, and a potential representing their mutual interaction. The membrane is modeled by a polygon
with Nm nodes connected by inextensible bonds and resisting bending through an angular spring of energy
Ea = K(θ −θ0)2, (1)
where the parameter θ0 = θm = 0 is the equilibrium value of the angle between two bonds, and K = Km is the bending stiffness
of the membrane. The coating scaffold is modeled, instead, as an open polygon with Ns nodes, rigid bonds and a bending energy
given by Eq.1 with K = Ks and θ0 = θs ≥ 0. In order to simulate a realistic structure, we chose Nm/Ns = 10, corresponding to
the ratio between the typical lipid distance in a biological membrane and the characteristic length of the COPII proteins in a
cage.51 For the membrane-scaffold interaction we employ a Lennard-Jones potential where the depth of the potential well is
equal to εLJ . Starting from a pseudo-circular equilibrium configuration, where the scaffold does not perturb the membrane, we
simulate the vesicle formation by changing gradually the equilibrium angle of the scaffold θs. The simulations are performed
using the LAMMPS molecular dynamics simulator package64 with a constant NVE integration and the addition of a viscous
damping force to reduce oscillations.
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Figure 1. Aggregation of neuroserpin with statins or betulin a) 100µg protein of HeLa cells or treated with 10µM PRA
or 5µM SIM or 0.1µM rosuvastatin or 1µM rosuvastatin or 20µM betulin were loaded on 10% native gel and transferred on
PVDF membrane. The sheet was incubated with anti-neuroserpin (ab32901, Abcam, 1:500) overnight at 4◦C and then with the
secondary antibody anti goat-HRP (1:5000, ECL Blotting reagents (GE Healthcare RPN2109) / SuperSignal West Femto
Maximum Sensitivity Substrate, Thermo scientific) for 1h at room temperature. Ponceau S solution (P7170, Sigma) was used
to verify the correct loading of the samples. b) Effect of statins or betulin treatments on the level of expression of neuroserpin
or HMGCR. 10µg total protein were loaded on 10% polyacrilamide gel, transferred on PVDF and incubated with
anti-neuroserpin (ab32901, AbCAM, 1:500) or with anti-HMGCR (1:1000, MAB5374, Millipore) overnight at 4◦C). Vinculin
(1:10000, Sigma) was used as housekeeping.
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Figure 2. Duolink In situ Staining of neuroserpin in HeLa untretaed or treated with SIM or PRA. a) Hela-GFP and
Hela cells were mixed 1:1 and treated with 5µM SIM or 10µM PRA up to 8 days, fixed in 3.7% paraformaldeide and incubated
with the primary antibody anti-neuroserpin (Ab32901, Abcam) coniugated PLA probes (1:50), overnight at 4◦C. The presence
of aggregates are visualized using Duolink in Situ staining according to the manufacturer’s instructions. Nuclei are stained with
DAPI. Images are acquired by Leica SP2 laser scanning confocal microscope. Each red spot represents a neuroserpin aggregate.
b) The number of spots per cell for each condition reported in panel a is quantified as described in the methods section.
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Figure 3. Effect of rosuvastatin and betulin on neuroserpin aggregation and cholesterol level. a) Hela-GFP and Hela
cells were mixed 1:1, treated with 0.1µM rosuvastatin or 20µM betulin for 8days, fixed in 3.7% paraformaldeide and incubated
with the primary antibody anti-neuroserpin (Ab32901, Abcam) coniugated PLA probes (1:50), overnight at 4◦C. The presence
of aggregates are visualized using Duolink in Situ staining according to the manufacturer’s instructions. Nuclei are stained with
DAPI. Images are acquired by Leica SP2 laser scanning confocal microscope. Each red spot represents a neuroserpin aggregate.
The number of spots per cell for each condition in the images showed in this panel is quantified as described in the methods
section. b) Untreated or treated cells with 0.1µM rosuvastatin or 20µM betulin (8 days) were fixed with 3.7% paraformaldeide
and then incubated with TNM-AMCA (1µM) to stain cholesterol for 1h at room temperature. Images were acquired by Leica
SP2 laser scanning confocal microscope.
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Figure 4. Detection of cholesterol with TNM-AMCA in untreated and treated HeLa cells after statins treatments.
Untreated or 5µM SIM or 10µM PRA treated HeLa cells for the time reported in the figure, were fixed with 3.7%
paraformaldeide and then incubated with TNM-AMCA (1µM) to stain cholesterol for 1h at room temperature. Images were
acquired by Leica SP2 laser scanning confocal microscope.
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Figure 5. Level of expression of SREBP1 and SREBP2 after SIM or PRA treatment in Hela cells. Subconfluent cells
are fixed with 3.7%paraformaldeide after 8 days treatment with statins and incubated with anti-SREBP1 (1:100, ab28481) or
anti SREBP-2 (1µg/ml ab30682, Abcam) overnight at 4◦C. Next, the cells are incubated with anti-rabbit Alexa Fluo488 for 1h
at room temperature. Actin is stained with 1µg/ml Actistain-555 phalloidin for 1h at room temperature. Nuclei are stained with
DAPI. Untreated cells are also shown for reference. Images are acquired by Leica SP2 laser scanning confocal microscope.
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Figure 6. a) Level of expression of SREBP1 and SREBP2 after rosuvastatin or betulin treatment in Hela cells.
Subconfluent cells a fixed with 3.7%paraforldeide after 8 days of rosovastatin (0.1µ M) or betulin (20µM) treatment and
incubated with anti-SREBP1 ( 1:100, ab28481) or anti SREBP-2 (1µg/ml ab30682, Abcam) overnight at 4◦ C. Then, the cells
are incubated with anti-rabbit AlexaFluo488 for 1h at room temperature. Nuclei are stained with DAPI. Untreated cells are also
shown for reference. Images are acquired by Leica SP2 laser scanning confocal microscope. b) Western blot of SREBP1 and
SREBP2 in Hela cells untreated and after 8 days of treatment with (20µM betulin. 10µg total protein were loaded on 10%
polyacrilamide gel, transferred on PVDF and incubated or anti-SREPB1 (1:500, ab28481, AbCam) or anti-SREBP2 (1:100,
ab30682, AbCam) were used overnight at 4◦C. Mouse anti-al pha Tubulin antibody (1:5000, Sigma) for 1h at room
temperature was used as housekeeping. A secondary antibody anti goat-HRP (1:5000, ECL Blotting reagents (GE Healthcare
RPN2109) / SuperSignalTMWest Femto Maximum Sensitivity Substrate, Thermo scientific) was used for 1h at room
temperature to detect chemiluminiscence. The bands reported are the precursor of SREBP1 and SREBP2, pre-SREBP
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a)
b)
Figure 7. Numerical simulations show protein aggregation induced by impairment of trafficking. a) The main figure
shows the average number of aggregates observed at a fixed time as a function of kout/kin, the ratio between rate of exit from
the ER by means of vesicular transport and the rate of protein production. A reduced value of kout leads to the formation of
aggregates. The inset shows the time dependence of the average number of aggregates for different values of kout. b) The phase
diagram of the vesicle formation model. The stiffness ratio between the membrane and the external scaffold Km/Ks as a
function of the intensity of the mutual interaction with respect to the scaffold rigidity εLJ/Ks. For soft membranes there is
almost always vesicle formation (yellow zone) or the breaking of the coat-membrane interface, if binding is not strong enough
(white zone). Increasing the membrane stiffness leads to a new phase appears where the coat-membrane interface is stable but
vesicle can not form (grey zone). Typical configurations in the different phases are reported on the right-hand side of the panel.
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